LILRB4 and neoplasm: In more recent findings, LILRB4 was shown to bind CD166 (activated leukocyte adhesion molecule, ALCAM) and serum apolipoprotein E (APOE), which mediate tumor cell growth and acute myeloid leukemia, respectively [35].